Rare Disease Patients Can Access Just One-Third of Medicines Available in Rest of Europe, Says IPHA

Just one-third of medicines for rare diseases licensed for patients in Europe are available in Ireland, according to new figures released on Rare Disease Day by the Irish Pharmaceutical Healthcare Association (IPHA), the representative body for the research-based pharmaceutical industry.   

Read more

IPHA defends industry against ‘baseless’ charge of ‘predatory’ pricing

The Irish Pharmaceutical Healthcare Association (IPHA) has defended the industry against a charge of ‘predatory’ pricing by the National Centre for Pharmoeconomics (NCPE). 

The NCPE is the State body that advises the Health Service Executive on the cost-effectiveness of medicines.

IPHA said the claim, made during a radio interview this week, amounted to an “accusation of illegality against the industry”.

 

Read more

IPHA hosts digital engagement seminar as healthcare storytelling evolves

Ever wondered why Facebook is serving you more and more ads for ways to take better care of health or your video feed features patients telling their stories of recovery from serious illnesses?

Read more

Pharmaceutical industry has ‘central role’ in improving cancer services

On World Cancer Day, pharmaceutical innovators have said they have a central role in delivering better cancer services for Irish patients over the coming years.

The Irish Pharmaceutical Healthcare Association (IPHA), which represents the research-based pharmaceutical industry, called on policymakers, clinicians, researchers and industry leaders to continue to work together on improving cancer outcomes for patients.

Read more

Government recognises ‘very significant work’ by industry on Brexit planning

The Government has recognised the industry for “very significant work” in planning for Brexit.

At the Oireachtas Committee on Health on Wednesday, the Secretary General of the Department of Health, Jim Breslin, outlined the steps the health authorities, working with industry and other stakeholders, are taking to secure the supply of medicines to patients after Brexit.

Read more

European lawmakers on course to weaken IP incentives environment

Lawmakers in Brussels are on track towards weakening the environment for the discovery and adoption of medical innovation, potentially putting at risk the development of new treatments and high-quality jobs at the frontiers of research.

Read more

Brexit demands us all to work together for patients

There’s a saying in Brussels called going ‘into the tunnel’. It’s when negotiators get together to try to plot a path to resolving Brexit. As the political turmoil continues, one certainty is that pharmaceutical innovators have been meticulously planning for Brexit. For two years or more, they have been reorganising supply chains and revising regulatory approvals. This work is critical in minimising the risk of disruption to the supply of medicines to patients after March 29th.

Read more